Search Videos and More
News
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
News
RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
News
Dana-Farber Researchers to Present Two Plenary Studies and Additional Late-Breaking Cancer Research at 2026 ASCO
Dana-Farber Cancer Institute researchers will present findings at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) from several studies with compelling and potentially practice-changing results spanning multiple cancer types, including pancreatic, prostate, breast, and multiple myeloma.
News
Dana-Farber Research News 05.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.
Course
Early Detection and Interception of Cancer: Current Practice Recommendations and Novel Emerging Approaches
Elevate your approach to cancer prevention with this dynamic course offering practical guidance on current screening practices, management of high-risk populations, and the integration of emerging early detection technologies into clinical care.
News
RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.
News
AI Tool Could Speed Discovery of New Cancer Drug Targets
Many cancer therapies work by docking into specific “binding pockets” on the surface of proteins that are driving the disease. Scientists are continually searching for new binding sites for future cancer drugs, but this process can be slow and cumbersome.
Document
Turning Point focused on Women's Cancers
Cultivating the next generation of scientists.
News
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians
Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).
News
Stuart Orkin Awarded Breakthrough Prize in Life Sciences
Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).
News
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
News
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.